- Shionogi’s 1Q operating income: 28.11 billion yen, down 40% year-over-year (y/y), missing the estimate of 31.91 billion yen.
- Net income for the same period: 30.64 billion yen, a decrease of 28% y/y, missing the estimate of 33.35 billion yen.
- Net sales: 97.59 billion yen, down 11% y/y, but slightly above the estimate of 96.5 billion yen.
- R&D expenses increased by 18% y/y to 29.43 billion yen, higher than the estimated 24.73 billion yen.
- First half forecast remains unchanged:
- Net sales: 210.00 billion yen
- Operating income: 69.00 billion yen
- Net income: 66.50 billion yen
- 2025 full-year forecast expectations:
- Operating income: 160.00 billion yen, estimate 154.6 billion yen
- Net income: 163.00 billion yen, estimate 158.42 billion yen
- Net sales: 455.00 billion yen, estimate 433.85 billion yen
- Dividend: 170.00 yen, estimate 168.33 yen
- Analyst recommendations:
- 8 buys
- 7 holds
- 1 sell
A look at Shionogi & Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shionogi & Company Ltd., a pharmaceutical company known for developing prescription and over-the-counter drugs as well as diagnostics, has been assessed with a mix of Smart Scores across various factors. With a solid outlook in growth and resilience, the company seems poised for long-term success. The growth score of 4 indicates a positive trajectory in expanding its business operations, while the resilience score of 4 reflects the company’s ability to withstand market challenges effectively.
Although the momentum score for Shionogi & Co is at 2, suggesting some room for improvement in this aspect, the overall outlook remains promising. With average scores in value and dividend, the company is seen as holding a balanced position in terms of its financial health and return to shareholders. Investors may find Shionogi & Co a compelling choice for long-term investment considering its strengths in growth and resilience.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
